A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes

Trial Profile

A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs GSK 2292767 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Aug 2017 Status changed from recruiting to completed.
    • 06 Jul 2017 Planned End Date changed from 4 Aug 2017 to 23 Aug 2017.
    • 06 Jul 2017 Planned primary completion date changed from 13 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top